Variables No. of Patients Mean survival (months) 14 months PFS proportion (%) Hazard Ratio P value
Age ≤40 years 25 11.83(10.10-13.55) 57 1 0.187
>40 years 23 10.22 (9.09-12.30) 34.9 1.82  
Grade III 31 12.88(11.84-13.91) 71 1 <0.0001
  IV 17 8.2 (6.06-10.36) 0 6.60  
Position Frontal 31 11.63(10.10-13.15) 49.9 1 0.284
  Others 17 10.57(8.68-12.47) 37.4 1.60  
Therapy CT+RT 21 13.85(13.56-14.13) 71.1 1 <0.0001
  RT 9 11.22 61.1 2.68  
  No 18 8 (5.94-10.06) 0 7.60  
MGMT Methylation status        
G-III Methylated 22 13.62(12.89-14.35) 83.3 1 0.026
Un-methylated 9 11.11(8.40- 13.82) 44.7 5.40  
G-IV Methylated 14 9.40(7.27-11.53) 15.7 1 0.001
Unmethylated 3 2.67(1.60-3.74) 0 5.96  
TP53 Methylation status        
G-III Methylated 10 13.20(11.71-14.68) 90 1 0.274
Unmethylated 21 12.72(11.37-14.07) 56.8 3.03  
G-IV Methylated 4 4.25(0.83-7.67) 25 3.54 0.016
Unmethylated 13 9.51(7.28-11.75) 17.9 1  
CDKN2A Methylation status        
G-III Methylated 11 13.10(11.43-14.77) 90 1 0.345
Unmethylated 20 12.75(11.43-14.07) 60.7 2.65  
G-IV Methylated 6 8.17(4.76-11.58) 16.7 1.02 0.961
Unmethylated 11 8.18(5.48-10.88) 35.4 1  
Table 2: Univariate analysis showing 14 month PFS proportion.